A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
Recruiting now · Phase 1/Phase 2
Conditions studied: Propionic Acidemia
In brief
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
Key facts
- Study ID
- NCT05130437
- Run by
- ModernaTX, Inc.
- People needed
- 50
- Starts
- 2021-11-09
- Expected to finish
- 2031-12-04
- Last updated by the study team
- 2026-03-23
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participated in Study mRNA-3927-P101.
- Completed the EOT/ET visit in Study mRNA-3927-P101 and enroll in this study such that the first dose in this study is planned to be within 14±3 days of the last dose of mRNA-3927 in the mRNA-3927-P101 study.
You may not qualify if…
- Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
- Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
- History of liver and/or kidney transplant.
Where it is running
- Great Ormond Street Hospital for Children NHS Foundation Trust — London, United Kingdom (enrolling)
- University of Stanford Medical Center — Palo Alto, California, United States (enrolling)
- University of Michigan Hospitals — Ann Arbor, Michigan, United States (enrolling)
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
- Duke University Medical System (Duke Health) — Durham, North Carolina, United States (enrolling)
- The Children's Hospital of Philadelphia (CHOP) — Philadelphia, Pennsylvania, United States (enrolling)
- Texas Children's Hospital — Houston, Texas, United States (enrolling)
- Hospital For Sick Children — Toronto, Ontario, Canada (enrolling)
- Fujita Health University Hospital — Toyoake-shi, Akita, Japan (enrolling)
- Tohoku University Hospital — Sendai, Miyagi, Japan (enrolling)
- Willink Biochemical Genetics Unit - Manchester — Manchester, England, United Kingdom (enrolling)
- University Hospital Birmingham NHS Foundation Trust — Birmingham, West Midlands, United Kingdom (enrolling)
- Erasmus MC -Dr. Molewaterplein 40 — Rotterdam, South Holland, Netherlands
- Universitair Medisch Centrum Utrecht - PPDS — Utrecht, Netherlands
- King Faisal Specialist Hospital & Research Centre — Riyadh, Ar Riya, Saudi Arabia
- King Abdullah Children's Specialist Hospital — Riyadh, Ar Riya, Saudi Arabia
- Hospital Universitario Cruces — Barakaldo, Vizcaya, Spain
- Hospital Universitario 12 de Octubre — Madrid, Spain
- AP-HM- Hôpital de La Timone — Marseille, France
- Hôpital Necker - Enfants Malades — Paris, France
- Birmingham Women's and Children's NHS Foundation Trust — Birmingham, West Midlands, United Kingdom
- Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.